Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency

Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency

Approximately 10% of patients are unable to synthesize CA 19.9 (Lewis-negative), and these results are erroneously considered false-negatives. The aim of this study was to confirm that CA 19.9 cannot be detected by immunoassays in Lewis-negative patients. CA 19.9 levels were measured by immunologica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anticancer research 2018-10, Vol.38 (10), p.5883-5888
Hauptverfasser: Parra-Robert, Marina, Santos, Víctor Molina, Canis, Silvia Miró, Pla, Xavier Filella, Fradera, Josep Maria Augé, Porto, Rafael Molina
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers, Tumor - analysis
CA-19-9 Antigen - metabolism
Cancer
Diagnostic systems
Genotype & phenotype
Humans
Immunoassays
Immunology
Lewis Blood-Group System - metabolism
Neoplasms - diagnosis
Neoplasms - metabolism
Patients
Phenotype
Phenotypes
Prognosis
Serum levels
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Approximately 10% of patients are unable to synthesize CA 19.9 (Lewis-negative), and these results are erroneously considered false-negatives. The aim of this study was to confirm that CA 19.9 cannot be detected by immunoassays in Lewis-negative patients. CA 19.9 levels were measured by immunological assays and Lewis phenotype was determined by the haemagglutination reaction. Patients with Lewis phenotype (a+b-) or (a-b+) had significantly higher CA 19.9 levels than Lewis-negative patients with active cancer (p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12931